NCT06752681
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06752681
Title To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Day One Biopharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Site: 001-058 RECRUITING New Haven Connecticut 06510 United States Details
Site: 001-063 RECRUITING Lake Mary Florida 32746 United States Details
Site: 001-064 RECRUITING Sarasota Florida 34232 United States Details
Site: 001-060 RECRUITING Indianapolis Indiana 46202 United States Details
Site: 001-059 RECRUITING Grand Rapids Michigan 49546 United States Details
Site: 001-039 RECRUITING New York New York 10021 United States Details
Site: 001-073 RECRUITING Oklahoma City Oklahoma 73104 United States Details
Site: 001-065 RECRUITING Nashville Tennessee 37203 United States Details
Site: 001-069 RECRUITING Houston Texas 77030 United States Details
Site: 001-057 RECRUITING San Antonio Texas 78229 United States Details
Site: 011-013 RECRUITING Vancouver British Columbia V5Z 4E6 Canada Details
Site: 011-005 RECRUITING Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field